Bortezomib (marketed as Velcade™ by Millenium Pharmaceuticals) is a "first-in-class" proteasome inhibitor. It is the best studied of a next generation of anti-myeloma drugs, and is also a potential treatment for plasma cell leukemia. more...
Bortezomib works by blocking the action of 26S proteasome, which is a multicatalytic enzyme whose function is to degrade abnormal or misfolded proteins targeted for destruction. There is emerging evidence that 26S proteasome plays a role in myeloma and lymphoma.
The Multiple Myeloma Research Foundation was responsible for a substantial amount of the funding for the development and testing of this drug.
Bortezomib is associated with peripheral neuropathy in 30% of patients; occasionally, it can be painful. This can be worse in patients with pre-existing neuropathy. In addition, myelosuppression as neutropenia and thrombocytopenia can also occur and be dose limiting.
- Millenium Pharmaceuticals website on Velcade™
- International Myeloma Foundation article on Velcade™
- US Food and Drugs Administration on Velcade™
- Dedicated website for European audience
Read more at Wikipedia.org